Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum

Drug and Alcohol Dependence

Volumn 115, Issue 1-2, 2011, Pages 150-155

  Johnson, Matthew W ^a   MacLean, Katherine A ^a   Reissig, Chad J ^a   Prisinzano, Thomas E ^b   Griffiths, Roland R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Hallucinogen; Humans; Kappa opioid agonist; Psychedelic; Salvia divinorum; Salvinorin A

Indexed keywords

PLACEBO; PSYCHEDELIC AGENT; SALVINORIN A; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HALLUCINOGEN RATING SCALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MYSTICISM SCALE; NORMAL HUMAN; PLANT LEAF; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOLOGY; SALVIA; SALVIA DIVINORUM; SELF REPORT; SIDE EFFECT; SPATIAL ORIENTATION; TREMOR;

ADULT; DITERPENES, CLERODANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALLUCINOGENS; HUMANS; MALE; PLANTS; PSYCHOPHARMACOLOGY; RECEPTORS, OPIOID, KAPPA; RETROSPECTIVE STUDIES; SALVIA; YOUNG ADULT;

LAMIACEAE; SALVIA DIVINORUM;

EID: 79955531128     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.11.005     Document Type: Article

References (31)

1. Baggott M.J., Erowid E., Erowid F., Galloway G.P., Mendelson J. Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend. 2010, 111:250-256.
2. Braida D., Limonta V., Capurro V., Fadda P., Rubino T., Mascia P., Zani A., Gori E., Fratta W., Parolaro D., Sala M. Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol. Psychiatry 2008, 63:286-292.
3. Bücheler R., Gleiter C.H., Schwoerer P., Gaertner I. Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage). Pharmacopsychiatry 2005, 38:1-5.
4. Butelman E.R., Harris T.J., Kreek M.J. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology 2004, 172:220-224.
5. Carlezon W.A., Beguin C., DiNieri J.A., Baumann M.H., Richards M.R., Todtenkopf M.S., Rothman R.B., Ma Z., Lee D.Y., Cohen B.M. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J. Pharmacol. Exp. Ther. 2006, 316:440-447.
6. Fahn S., Tolosa E., Marín C. Clinical rating scale for tremor. Parkinson's Disease And Movement Disorders 1993, 225-234. Williams & Wilkins, Baltimore. J. Jankovic, E. Tolosa (Eds.).
7. Fantegrossi W.E., Kugle K.M., Valdes L.J., Koreeda M., Woods J.H. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav. Pharmacol. 2005, 16:627-633.
8. González D., Riba J., Bouso J.C., Gomez-Jarabo G., Barbanoj M.J. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend. 2006, 85:157-162.
9. Griffiths R.R., Richards W.A., McCann U., Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006, 187:268-283.
10. Hood R.W., Ghorbani N., Watson P.J., Ghramaleki A.F., Bing M.N., Davison H.K., Morris R.J., Williamson W.P. Dimensions of the mysticism scale: confirming the three-factor structure in the United States and Iran. J. Sci. Study Relig. 2001, 40:691-705.
11. Johnson M.W., Richards W.A., Griffiths R.R. Human hallucinogen research: Guidelines for safety. J. Psychopharmacol. 2008, 22:603-620.
12. Kivell B., Prisinzano T.E. Kappa opioids and the modulation of pain. Psychopharmacology 2010, 210:109-119.
13. Lange J.E., Daniel J., Homer K., Reed M.B., Clapp J.D. Salvia divinorum: effects and use among YouTube users. Drug Alcohol Depend. 2010, 108:138-140.
14. McCurdy C.R., Sufka K.J., Smith G.H., Warnick J.E., Nieto M.J. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol. Biochem. Behav. 2006, 83:109-113.
15. Mello N.K., Negus S.S. Interactions between kappa opioid agonists and cocaine: preclinical studies. Ann. N.Y. Acad. Sci. 2000, 909:104-132.
16. Mowry M., Mosher M., Briner W. Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J. Psychoactive Drugs 2003, 35:379-382.
17. Ott J. Ethnopharmacognosy and human pharmacology of Salvia divinorum and salvinorin A. Curare 1995, 18:103-129.
18. Ott J. Pharmacotheon: Entheogenic Drugs, Their Plant Sources And History 1996, Natural Products Co, Kennewick, WA. 2nd ed.
19. Paulzen M., Gründer G. Toxic psychosis after intake of the hallucinogen salvinorin A. J. Clin. Psychiatry 2008, 69:1501-1502.
20. Prisinzano T.E. Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci. 2005, 78:527-531.
21. Przekop P., Lee T. Persistent psychosis associated with Salvia divinorum use. Am. J. Psychiatry 2009, 166:7.
22. Roth B.L., Baner K., Westkaemper R., Siebert D., Rice K.C., Steinberg S., Ernsberger P., Rothman R.B. Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11934-11939.
23. Sheffler D.J., Roth B.L. Salvinorin A: the magic mint hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol. Sci. 2003, 24:107-109.
24. Siebert D.J. Salvia divinorum and salvinorin A: new pharmacologic findings. J. Ethnopharmacol. 1994, 43:53-56.
25. Singh S. Adolescent salvia substance abuse. Addiction 2007, 102:823-824.
26. Strassman R.J., Qualls C.R., Uhlenhuth E.H., Kellner R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch. Gen. Psychiatry 1994, 51:98-108.
27. Valdes L.J. Salvia divinorum and the unique diterpene hallucinogen, salvinorin (divinorin) A. J. Psychoactive Drugs 1994, 26:277-283.
28. Vohra R., Seefeld A., Cantrell F.L., Clark R.F. Salvia divinorum: exposures reported to a statewide poison control system over 10 years. J. Emerg. Med. 2009, (September). [Epub ahead of print].
29. Walsh S.L., Strain E.C., Abreu M.E., Bigelow G.E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 2001, 157:151-162.
30. Wang Y., Tang K., Inan S., Siebert D., Holzgrabe U., Lee D.Y., Huang P., Li J.G., Cowan A., Liu-Chen L.Y. Comparison of pharmacological activities of three distinct kappa ligands (salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J. Pharmacol. Exp. Ther. 2005, 312:220-230.
31. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., Kreek M.J. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology 2005, 179:551-558.